The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.

Slides:

Advertisements

Similar presentations

Tuberculosis incidence and risk factors among adult patients receiving HAART in Senegal: a 7-year cohort study Assane DIOUF et al. IRD/UMR 145 CRCF, CHNU.

Advertisements

STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.

Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.

The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.

Prevalence of and Progression to Abnormal Non-Invasive Markers of Liver Disease (APRI and FIB-4) among US HIV-infected Youth Kapogiannis B, Leister E,

The Progression of Liver Fibrosis is Associated with the Severity of the HIV Disease in HIV-HCV Co-infected Female Patients Mohammad K. Mohammad 1, Babu.

Late HIV Diagnoses, Georgia,

1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.

* Pre- and Post-HAART eras defined as before or after 07/01/96. ** For comparison of HIV positive to HIV negative IRs within Pre- or Post-HAART eras. ***

HIV Disease in Older Patients Donna M. Gallagher, ANP The International AIDS Society–USA DM Gallagher, ANP. Presented at IAS–USA/RWCA Clinical Conference,

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

Introduction DCDOH supports HIV test and treat activities - increased number of HIV tests performed, emphasis on earlier linkage to care. Limited data.

Disparate Virologic Response to HAART between Ethnicities Amy Weintrob 1,2, Greg Grandits 2,3, Brian Agan 2,4, Anuradha Ganesan 2,5, Nancy Crum-Cianflone.

Impact of tuberculosis screening and isoniazid preventive therapy on incidence of TB and death in the TB/HIV in Rio de Janeiro (THRio) study B. Durovni1,2,

Patient Empowerment Impacts Medication Adherence among HIV-Positive Patients in the Veteran’s Health Administration Tan Pham 1,2,3, Kristin Mattocks 1,2,

Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.

Liver fibrosis regression after anti HCV therapy and the rate of death, liver-related death, liver- related complications, and hospital.

Is monitoring for CD4 counts still needed for the management of patients with long- term HIV RNA suppression? Andrew Hill, Liverpool University, UK.

1 Is Managed Care Superior to Traditional Fee-For-Service among HIV-Infected Beneficiaries of Medicaid? David Zingmond, MD, PhD UCLA Division of General.

Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.

The Effect of Gender Based Violence (GBV) on Mortality: a longitudinal study of US women with & at risk for HIV Kathleen M. Weber Steve R. Cole, Jane Burke-Miller,

Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.

Washington D.C., USA, JULY Rulin C. Hechter 1 MD,PhD Jean Q. Wang 1 PhD Margo A. Sidell 1 ScD William J. Towner 2 MD 1 Dept.

Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents Roger Bedimo, MD; Song Zhang, PhD; Henning.

Fatal and Non-fatal Hepatic Failure in HIV-infected versus HIV-uninfected Persons Enrolled in Kaiser Permanente California (KP), a Large Managed Care Organization.

The Immunologic Efficacy of Antiretroviral Therapy among HIV-infected Patients in North America and Africa Elvin Geng* 1, Eric Vittinghoff 1, Jean Nachega.

Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.

Management and Development for Health (MDH)

Occult hepatitis B virus (HBV) and hepatitis C virus (HCV) viremia in women with and at-risk for HIV/AIDS Taylor L, Gholam P, Delong A, Rompalo A, Klein.

Impact of HSV-2 suppressive therapy with daily acyclovir on HIV-1 disease progression: a randomized placebo- controlled trial in Rakai, Uganda Steven J.

#735 KA Lichtenstein 1, C Armon 2, K Buchacz 3, AC Moorman 3, KC Wood 2, JT Brooks 3, and the HOPS Investigators 1 University of Colorado Health Sciences.

Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,

Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.

Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,

Poster 810 Race and Sex Differences in HAART Use and Mortality among HIV-infected Persons in Care DC Lemly 1, BE Shepherd 1, TM Hulgan 1, P Rebeiro 1,

Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.

1 RESIST Trials - Grade 3 or 4 AST, ALT or Total Bilirubin: Actions and Outcomes Action Taken: TPV/r N=748 CPI/r N=737 Total Number of Grade 3 or 4 ALT,

HIV Disease and Hepatitis C Virus (HCV) Co-Infection – Florida, 2011 HIV/AIDS & Hepatitis Program - Surveillance Section HIV Disease data from 1981 through.

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500.

Immune Discordance on Highly Active Antiretroviral Therapy Can Still be Regarded as a Therapeutic Success Nur F. Önen MD, MRCP 1, Rachel Presti MD PhD.

Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.

Factors Associated with Survival in HIV-Infected African Patients on Antiretroviral Therapy: The Impact of a Sampling-Based Approach to Address Losses.

1 The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART Authors: Harout Tossonian, Jesse.

Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,

MISSING DATA IN THE INFECTIOUS DISEASES INSTITUTE CLINIC DATABASE Agnes N Kiragga East Africa IeDEA investigators’ meeting 4-5 th May 2010 East African.

TREND AND RISK FACTORS FOR OBESITY AMONG HIV POSITIVE NIGERIANS ON ANTIRETROVIRAL THERAPY. Ezechi Lilian O. BSc, MSc, MEd Department of Home Economics.

The Impact of Darunavir/ritonavir (DRV/r) & Raltegravir (RAL) in the Clinic: A New Era for Treatment-Experienced Patients? M. Mugavero 1, H. Lin 1, J.

Long-Term Comparison of Nevirapine Versus Efavirenz When Combined with Other Antiretroviral Drugs in HIV-1 Positive Antiretroviral-Naïve Persons- The NNRTI.

Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.

Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Influence of the Timing of Antiretroviral Therapy.

Effect of ART on malaria parasitaemia and clinical episodes in adults in rural Uganda: A population-based cohort study Billy N. Mayanja 1, Kathy Baisley.

Herpes Simplex Virus Type 2 infection among U.S. military service members: Public Health Implications and Opportunities for HIV Prevention Christian T.

Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.

HIV co-receptor tropism in treatment-naïve patients: impact on CD4 decline and subsequent response to HAART Laura Waters, Sundhiya Mandalia, Adrian Wildfire,

Mortality during the first year of HAART in HIV-1-infected patients in 7 countries from Latin America and the Caribbean Suely H. Tuboi, MD, PhD On behalf.

Trends in Mortality in the Pre- & Post-HAART Eras among HIV-Infected Children in the U.S. Perinatal AIDS Collaborative Transmission Study (PACTS) ( )

HIV Infection Increases Risk of ASCUS and Subsequent Development of SILs Slideset on: Duerr A, Paramsothy P, Jamieson DJ, et al. Effect of HIV infection.

Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.

Texas Pediatric Society Electronic Poster Contest

Earlier treatment and lower mortality in infants Initiating ART at

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Clinical outcome after SVR: Veterans Affairs

San Francisco Department of Public Health

Chronic Kidney Disease in HIV Infection: An Urban Epidemic

Management and Development for Health (MDH)

Impact of Hepatitis C, HIV, or Both on Survival in Veterans in Care Before and After the Introduction of HAART (1996) SL Fultz, MD, MPH CH Chang, PhD AA.

Shawn L Fultz, MD MPH VACS Scientific Meeting, Feb 2004

Presentation transcript:

The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons Weintrob A 1, Gu W 2, Robertson J 1, Qin J 2, Ganesan A 1, Crum-Cianflone N 1, Wegner S 1, Follmann D 2, Agan B 1 1 Infectious Disease Clinical Research Program of the Uniformed Services University of the Health Sciences, Bethesda, MD, 2 National Institute of Allergy and Infectious Disease, Rockville, MD Background: Syphilis co-infection transiently decreases CD4 count and increases viral load (VL) in HIV-infected persons. With the continued increase in syphilis cases among those with HIV, understanding whether these changes affect time to AIDS or death is important. Methods: 2239 HIV seroconverters from a longitudinal US military cohort followed from 1986 – 2006 were analyzed to determine the effect of syphilis on time to AIDS and/or death. Confirmed syphilis was a positive RPR and treponemal test after HIV infection. Probable syphilis was a clinical diagnosis and treatment for syphilis. Subjects were compared using chi-square and Wilcoxon tests. Cox regression models were used to analyze survival data right censoring at HAART/last visit/1996 (Model A) or last visit (Model B, treating HAART as time-dependent variable). Results: Of the 2239, 205 (9%) had confirmed syphilis and 66 (3%) had probable syphilis. Those acquiring syphilis were more likely to be older, African American, male, and co-infected with hepatitis B/C or other STDs. There was no difference in time from imputed seroconversion to HIV diagnosis or in CD4 or VL at HIV diagnosis between those with and without syphilis. The rate of acquiring syphilis was lower in the pre-HAART era (HR 0.49, p<0.0001). In multivariate models of time to AIDS or death or time to death alone (Model A) adjusting for CD4, age, race, gender, and hepatitis B/C status, syphilis (confirmed + probable) was not associated with increased hazard (HR 0.99, 95% CI , and 1.57, 95% CI , respectively). Likewise, in Model B, syphilis was not associated with increased hazard of time to AIDS or death (HR 0.95, 95%CI ) or time to death alone (HR 1.53, 95%CI ). Results of all analyses were similar when syphilis was limited to confirmed cases. Conclusions: In a large, prospectively followed cohort of HIV seroconverters with equal access to free healthcare, syphilis co-infection did not affect time to AIDS or death HIV-infected subjects enrolled in the TACC NHS, an ongoing, prospective multicenter observational study which began in 1986, were analyzed. All subjects had negative HIV tests prior to their first positive HIV test allowing for an estimation of seroconversion date. Syphilis definitions: Confirmed = positive non-treponemal and treponemal assays Probable = received treatment for clinical diagnosis of syphilis Possible = positive non-treponemal assay only, no treatment Cox regression models were used to analyze time to death or AIDS (1993 CDC definition) right censoring at either: time of HAART initiation, last visit, or Jan 1, 1996 (model A) time of last visit, treating HAART as a time-dependent variable (model B) In the TACC HIV NHS, syphilis was more common in African Americans than in other ethnicities and more common amongst males than females. Those with syphilis were more likely to be infected with other sexually transmitted diseases including hepatitis B and C. Syphilis co-infection at least transiently decreases CD4 counts and increases HIV viral loads. The effects of syphilis on CD4 count and viral load however do not translate into faster progression to AIDS or death. Abstract Materials & Methods Results Results Conclusions 1 Palacios R, Jimenez-Onate F, Aguilar M, et al. Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients. J Acquir Immune Defic Syndr 2007;44: Buchacz K, Patel P, Taylor M, et al. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS 2004;18: Kofoed K, Gerstoft J, Mathiesen LR, Benfield T. Syphilis and human immunodeficiency virus (HIV)-1 co- infection; influence on CD4 T-cell count, HIV-1 viral load, and treatment response. Sex Transm Dis 2006;33: Burgi A, Crum-Cianflone NF, Pope B, et al. The negative effect of syphilis infections among HIV-infected persons on the CD4 cell count. The 44th Annual Meeting of the Infectious Disease Society of America Meeting, Toronto Canada, October 12-15, 2006 References Poster #H-2329 During syphilis co-infection, HIV viral loads increase and CD4 lymphocyte counts decrease. 1-4 The CD4 count decrease is transient; however, the viral load increase may remain after syphilis treatment. 1,2 These changes may be due to immune activation which enhances viral replication. Whether these changes affect clinical outcomes in HIV-infected persons with syphilis remains unclear. The objective of this study was to determine whether syphilis co- infection affected the time to death or AIDS diagnosis in subjects enrolled in the TriService AIDS Clinical Consortium (TACC) HIV Natural History Study (NHS). Introduction amedd.army.mil (202) phone (202) fax Baseline Characteristics Variable No syphilis (n=1920 ) Confirmed Syphilis (n=205 ) Probable Syphilis (n=66 ) Possible Syphilis (n= 48) P-value Age at seroconversion (years ± SD) 28 ± 729 ± 7 29 ± 8<.05 Race (%) European American African American Hispanic Other <.05 Gender (%) Male Female <.05 Rank (%) Enlisted Officer Time from seroconversion to HIV diagnosis (days ± SD) 319 ± ± ± ± Viral load at HIV diagnosis (log 10 c/ml ± SD) 4.8 ± 5.2 (n=857) 4.7 ± 4.9 (n=91) 4.9 ± 5.1 (n=17) 5.1 ± 5.3 (n=10) 0.27 CD4 count at HIV diagnosis (cells/mm 3 ± SD) 555 ± 262 (n=1709) 570 ± 237 (n=178) 523 ± 212 (n=59) 510 ± 195 (n=40) 0.43 Percent who started HAART <.05 Year of HAART start CD4 at HAART start (cells/mm 3 ±SD) 365 ± 212 (n=980) 382 ± 197 (n=135) 357 ± 211 (n=36) 319 ± 212 (n=27) 0.50 Viral load at HAART start (log 10 c/ml ± SD) 4.9 ± 5.4 (n=913) 4.7 ± 5.0 (n=130) 4.4 ± 4.7 (n=32) 5.0 ± 5.3 (n=27) 0.23 Hepatitis B co-infection (%)581210<.05 Hepatitis C co-infection (%)39 913<.05 # Other STDs (mean/person) <.05 Length of follow up (days ± SD) 1548± ± ± ±1307<.05 Time to Death or AIDS (n=1338)* Multivariate Cox regression censored at HAART, last visit, or Jan. 1, 1996 VariableReferenceHazard Ratio 95% CIp-value Syphilis**Yes – Age1 year – EthnicityCaucasian – GenderMale – CD4 count100 cells – 0.74< Hepatitis BYes – Hepatitis CYes – *VL was excluded from above model because of a significant number of subjects with missing baseline VLs. The effect of syphilis on time to death or AIDS did not change when VL was included in the model (n=410). **Syphilis = confirmed + probable cases. Results remain the same if analysis is limited to confirmed cases only. In a similar multivariate Cox regression censored at the same time points, syphilis had no significant effect on time to death alone (HR = 1.89, 95% CI 0.96 – 3.71, p=0.066). Time to Death or AIDS (n=1938)* Multivariate Cox regression censored at last visit with HAART treated as a time-dependent co-variate VariableReferenceHazard Ratio 95% CIp-value Syphilis**Yes – Age1 year – EthnicityCaucasian – GenderMale – CD4 count100 cells – 0.76< Hepatitis BYes – Hepatitis CYes – HAARTYes – 0.31< *VL was excluded from above model because of a significant number of subjects with missing baseline VLs. The effect of syphilis on time to death or AIDS did not change when VL was included in the model (n=1001). **Syphilis = confirmed + probable cases. Results remain the same if analysis is limited to confirmed cases only. Similarly, syphilis had no significant effect on time to death alone (HR = 1.54, 95% CI 0.85 – 2.78, p=0.16) in Cox regression with HAART treated as a time-dependent co-variate.